Clinical Trial

Conservative Treatments of Retinoblastoma

Study acronym: RETINO2011
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Conservative treatments of retinoblastoma (RETINO 2011) 1. -Multicentric non randomised, phase II study for the patients treated by chemoreduction (VP16, carboplatin) followed by chemothermotherapy without laser treatment at day 8 2. -Multicentric non randomised, phase II study for the patients with bilateral very asymmetric dis-ease (Group D eye on one of the eye) or unilateral presentation groups B/C/D according to the age and vitreous seeding 3. \- Multicentric non randomised, phase II study for the patients treated by 6 cycles of three drugs regimen and local treatments for bilateral group D eyes or on the only eye.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2016-08-09; most recent amendment 2025-11-21.
Status change: Recruiting → Active, Not Recruiting 2023-02-21
Trial Details
NCT Number NCT02866136
Lead Sponsor Institut Curie
Collaborators: Fondation Rothschild Paris
Conditions Retinoblastoma, Children, Retinal Neoplasm
Enrollment 133 participants
Start Date 2012-02
Primary Completion 2023-01 (estimated)
Study Completion 2035-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-24